Aug 11, 2025 | Benefits preservation, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
Specialty medications continue to drive a disproportionate share of prescription drug costs – often accounting for 60% or more of a pharmacy plan’s total spend. MedBen Rx’s Benefit Preservation helps plans manage these expenses without compromising...
Jul 29, 2025 | Biologics, Biosimilar, Cost Savings, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Savings
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....
Jul 11, 2025 | Comparative Effectiveness, Cost Savings, Drug costs, Evidence-based research, Formularies, High-value formulary, MedBen Rx, Rx Advertising, Rx Costs, Rx prices, Rx Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Jul 1, 2025 | Benefits preservation, Diabetes, GLP-1s, MedBen Rx, Ozempic, Rebates, Specialty Drugs, Spread Pricing, Transparency, Wegovy, Weight loss, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Feb 24, 2025 | Benefits preservation, Case Study, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the greatest...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
